Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China State Council Lines Up Tasks In Five Key Healthcare Reforms

This article was originally published in PharmAsia News

Executive Summary

China's General Office of the State Council recently released the tasks identified for five key healthcare reforms in 2009: speed up establishment of a basic medical care system; set up a national essential drug system; improve the grassroots medical care service system; promote uniformity in basic public healthcare; and push for reform pilots in public hospitals. According to the line-up of requirements, the national essential drug list is to be finalized by the end of November, with all drugs included in the drug catalog of the national basic medical insurance. Public hospital reform pilots will be conducted in about 100 hospitals of 12 prefecture cities identified from the Eastern, Central and Western regions of China. The State Council task force, which leads the deepening of the healthcare reform, will inspect the overall implementation by year end. (Click here for more - Chinese language)

You may also be interested in...



Novartis And The Medicines Company: Five Things To Worry About

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

QUOTED. 12 December 2019. Scott Whitaker

US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.

Horizon Teprotumumab's US Advisory Cmte. Likely To Focus On Labeling, Not Approval, Questions

FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.

UsernamePublicRestriction

Register

SC072300

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel